Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.

Journal

Blood, 2025

Authors

Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE

Learn More

BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.

Donate Today

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.

BC Cancer Research

Office of Research Administration

Population Health Sciences

Genome Sciences Centre

Terry Fox Laboratory

Molecular Oncology

Integrative Oncology

Lymphoid Cancer Research

Experimental Therapeutics

Clinical Research

Deeley Research Centre